Invasive fungal sinusitis-analysis of management scenario

Abstract

<p class="abstract"><strong>Background:</strong> The objective of the study was to analyse the outcomes after therapeutic treatment of invasive fungal sinusitis.</p><p class="abstract"><strong>Methods:</strong> A<strong> </strong>cross-sectional study consisting of 30 patients from<strong> </strong>January 2015-December 2005 in<strong> </strong>Jawaharlal<strong> </strong>Nehru<strong> </strong>medical<strong> </strong>college, department<strong> </strong>of<strong> </strong>ENT, Belagavi. Antifungal drugs were used like Amphotericin B-both non-liposomal & liposomal variety, and analysis of various parameters like its duration, efficacy and dosage was done in determining the prognosis. </p><p class="abstract"><strong>Results:</strong> The liposomal type of amphotericin B (AmBisone), which was used in 23 patients (76.6%) had a response rate of 65% and failure rate of 26%, with minimum dose of 50 mg/day to maximum dose of 200 mg/day. The maximum number of days used was for 46 days in 18 cases, which showed the effectiveness in controlling the infection. Amphotericin B deoxycholate (Fungizone) was used in 6 patients (20%) with response rate of 50% and failure rate of 33.3% and maximum dose given was 25 mg/day keeping a track of the renal profile. The total duration of treatment with Fungizone was for 14 days.</p><p><strong>Conclusions:</strong> Along with surgical intervention, we were able to combat this fatal disease in 56% patients which was the overall survival rate and liposomal variety was preferred as majority of the patients had deranged renal parameters on presentation. But certain constraints like non-affordability by poor patients, cost-effectiveness on long term usage, were there. So further studies about the availability of more safer and affordable antifungals should be done. </p>